In sorafenib-treated HCC, for example, high miR-21 expression (an oncomiR targeting PTEN) is linked to acquired therapeutic resistance: sorafenib induces miR-21 upregulation, which suppresses PTEN and activates Akt, thereby inhibiting autophagy and enabling resistance [75]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.